Keith L Black Selected Research

Potassium

9/2008	PDE5 inhibitors enhance tumor permeability and efficacy of chemotherapy in a rat brain tumor model.
3/2007	Calcium-activated potassium channels mediated blood-brain tumor barrier opening in a rat metastatic brain tumor model.
6/2003	Calcium-dependent potassium channels as a target protein for modulation of the blood-brain tumor barrier.
6/2002	Regulation of blood-brain tumor barrier permeability by calcium-activated potassium channels.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Keith L Black Research Topics

Disease

99	Neoplasms (Cancer) 06/2023 - 01/2002
67	Glioma (Gliomas) 06/2023 - 01/2002
42	Brain Neoplasms (Brain Tumor) 10/2021 - 06/2002
36	Glioblastoma (Glioblastoma Multiforme) 06/2023 - 12/2002
25	Alzheimer Disease (Alzheimer's Disease) 02/2024 - 12/2009
12	Cognitive Dysfunction 02/2024 - 03/2014
10	Breast Neoplasms (Breast Cancer) 04/2015 - 11/2003
7	Amyloid Plaque 02/2024 - 01/2011
7	Inflammation (Inflammations) 01/2022 - 07/2014
6	Amyloidosis 01/2022 - 01/2020
6	Disease Progression 01/2022 - 01/2011
4	Cerebral Amyloid Angiopathy (Congophilic Angiopathy) 11/2023 - 01/2020
4	Gliosis 10/2020 - 12/2009
4	Lung Neoplasms (Lung Cancer) 05/2015 - 01/2007
3	Tauopathies 02/2024 - 12/2016
3	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2024 - 03/2009
3	Meningioma (Meningiomas) 01/2023 - 08/2003
3	Astrocytoma (Pilocytic Astrocytoma) 04/2020 - 08/2004
3	Gliosarcoma 09/2008 - 07/2007
2	Brain Injuries (Brain Injury) 01/2024 - 01/2018
2	Oligodendroglioma 04/2020 - 05/2014
2	Neuroinflammatory Diseases 01/2020 - 01/2019
2	Wounds and Injuries (Trauma) 03/2016 - 02/2010
2	Triple Negative Breast Neoplasms 12/2013 - 01/2012
2	Carcinogenesis 11/2010 - 02/2007

Drug/Important Bio-Agent (IBA)

29	Proteins (Proteins, Gene)FDA Link 05/2024 - 03/2003
19	Retinaldehyde (Retinal)IBA 02/2024 - 01/2011
17	VaccinesIBA 06/2023 - 05/2004
17	Amyloid (Amyloid Fibrils)IBA 01/2023 - 12/2009
13	AntigensIBA 01/2024 - 07/2003
13	Neoplasm Antigens (Tumor Antigens)IBA 06/2023 - 03/2003
10	poly(malic acid)IBA 01/2019 - 01/2006
10	Antisense OligonucleotidesIBA 06/2014 - 10/2003
9	malic acid (malate)IBA 01/2023 - 03/2006
9	NanoconjugatesIBA 01/2022 - 03/2006
8	Temozolomide (Temodar)FDA LinkGeneric 01/2023 - 08/2005
8	CytokinesIBA 01/2019 - 01/2002
7	Peptides (Polypeptides)IBA 01/2022 - 02/2004
7	laminin 8IBA 10/2007 - 10/2003
6	Glatiramer Acetate (Copaxone)FDA Link 01/2022 - 11/2011
6	Monoclonal AntibodiesIBA 01/2012 - 06/2003
6	MorpholinosIBA 01/2012 - 10/2003
5	Biomarkers (Surrogate Marker)IBA 01/2024 - 07/2004
5	PolymersIBA 10/2021 - 01/2008
5	Laminin (Merosin)IBA 10/2012 - 10/2003
5	Messenger RNA (mRNA)IBA 02/2011 - 01/2003
5	polycefinIBA 04/2008 - 01/2006
4	Protein Isoforms (Isoforms)IBA 02/2024 - 08/2004
4	CurcuminIBA 01/2020 - 09/2015
4	Transferrin Receptors (Transferrin Receptor)IBA 01/2012 - 01/2006
4	Antineoplastic Agents (Antineoplastics)IBA 01/2011 - 06/2003
4	PotassiumIBA 09/2008 - 06/2002
4	CalciumIBA 09/2008 - 06/2002
4	NS 1619IBA 08/2008 - 06/2002
4	BradykininIBA 03/2007 - 06/2002
3	Amyloid beta-PeptidesIBA 11/2023 - 12/2009
3	Particulate MatterIBA 10/2023 - 11/2013
3	RNA (Ribonucleic Acid)IBA 01/2023 - 03/2006
3	Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)IBA 01/2023 - 03/2014
3	Immunoconjugates (Immunoconjugate)IBA 11/2020 - 01/2019
3	Contrast MediaIBA 01/2020 - 05/2015
3	GadoliniumIBA 01/2020 - 01/2013
3	AntibodiesIBA 01/2019 - 10/2007
3	Biopolymers (Biopolymer)IBA 01/2019 - 03/2006
3	ErbB Receptors (EGF Receptor)IBA 12/2016 - 10/2012
3	Green Fluorescent ProteinsIBA 08/2015 - 06/2003
3	EnzymesIBA 09/2014 - 09/2008
3	Cancer VaccinesIBA 09/2014 - 02/2004
3	ProdrugsIBA 04/2013 - 11/2010
3	Membrane Proteins (Integral Membrane Proteins)IBA 02/2012 - 11/2002
3	DNA (Deoxyribonucleic Acid)IBA 05/2009 - 04/2004
3	Calcium-Activated Potassium Channels (Calcium-Activated Potassium Channel)IBA 03/2007 - 06/2002
3	InterleukinsIBA 09/2006 - 10/2002
3	laminin 9IBA 01/2006 - 08/2004
3	Carboplatin (JM8)FDA LinkGeneric 08/2005 - 06/2003
2	Neuraminidase (Sialidase)IBA 06/2023 - 09/2014
2	N-Acetylneuraminic Acid (Sialic Acid)IBA 06/2023 - 09/2014
2	DisulfidesIBA 01/2023 - 03/2006
2	leucyl-leucyl-leucineIBA 01/2023 - 10/2010
2	Small Interfering RNA (siRNA)IBA 01/2023 - 06/2004
2	epidermal growth factor receptor VIIIIBA 10/2021 - 12/2016
2	Platelet-Derived Growth Factor Receptors (Platelet-Derived Growth Factor Receptor)IBA 01/2021 - 01/2020
2	Transcription Factors (Transcription Factor)IBA 01/2018 - 01/2007
2	Therapeutic UsesIBA 08/2015 - 09/2009
2	CamptothecinIBA 04/2013 - 09/2010
2	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2012 - 09/2008
2	Nucleosomes (Nucleosome)IBA 01/2012 - 10/2007
2	Complementary DNA (cDNA)IBA 11/2011 - 12/2002
2	Trastuzumab (Herceptin)FDA Link 02/2011 - 04/2010
2	Non-Steroidal Anti-Inflammatory Agents (NSAIDs)IBA 01/2011 - 09/2008

Therapy/Procedure

39	Therapeutics 01/2023 - 03/2002
19	Drug Therapy (Chemotherapy) 01/2023 - 11/2003
17	Immunotherapy 06/2023 - 03/2003
6	Radiotherapy 01/2023 - 05/2004
6	Lasers (Laser) 01/2020 - 07/2004
4	Adjuvant Radiotherapy 06/2016 - 07/2005
3	Oral Administration 04/2010 - 06/2008
2	Immunomodulation 10/2020 - 12/2009
2	Intravenous Injections 01/2020 - 10/2007
2	Craniotomy 03/2016 - 08/2012